Harness the power of single or dual ISH to visualize and quantify nucleic acids with precision.
Uncover detailed expression data using CellCarta’s ISH services. We offer all methods of probe detection, including fluorescence (FISH), chromogenic (CISH), and silver (SISH) ISH assays.
Whether your study requires single or dual ISH, our team of experts deliver quality and precision at any stage of development.
ISH technology provides detailed insight into gene expression within its tissue context, but their standard methodologies are a labor-intensive process.
At CellCarta, we’ve implemented automated platforms to optimize ISH workflows and increase reproducibility.
CellCarta has expertise in multiple key ISH platforms, including:
All equipment is qualified and cross-validated by all our global labs to ensure consistent quality and reproducibility.
For any clinical trial phase and IVD/CDx development, CellCarta can develop and validate custom ISH assays.
Cytogenetic FISH assays have been deployed for diagnosis, prognosis, and therapeutic . Our semi-automated FISH process can handle up to 50 slides in one run.
SISH assays are performed on the automated Ventana Benchmark XT and Ultra systems, which can handle up to 30 slides in one run.
ISH technology provides detailed insight into gene expression within its tissue context, but their standard methodologies are a labor-intensive process.
At CellCarta, we’ve implemented automated platforms to optimize ISH workflows and increase reproducibility.
CellCarta has expertise in multiple key ISH platforms, including:
All equipment is qualified and cross-validated by all our global labs to ensure consistent quality and reproducibility.
For any clinical trial phase and IVD/CDx development, CellCarta can develop and validate custom ISH assays.
Cytogenetic FISH assays have been deployed for diagnosis, prognosis, and therapeutic . Our semi-automated FISH process can handle up to 50 slides in one run.
SISH assays are performed on the automated Ventana Benchmark XT and Ultra systems, which can handle up to 30 slides in one run.
CellCarta has extensively evaluated the new RNAscope® (ACD) nucleic acid ISH technology to provide in-depth mRNA data in FFPE tissues. For your specific mRNA ISH assay, this technology undergoes custom validation to fine-tune the procedure to the needs of your specific sample.
Our ISH services are built for precision, from early discovery phases to clinical deployment.
Full ISH Method Coverage
Multi-Modal Capabilities
Global Execution
Integrated Automation
Suited for Clinical Use
Combine our ISH assays with these other expert services to receive a comprehensive view of your transcriptomics data.
Insights into the abundance, distribution, and localization of your antigen of interest.
Cutting-edge digital and AI-powered pathology services to advance your clinical trials.
Genomics solutions for all phases of drug development and CDx development.
in situ hybridization (ISH) is a technique that enables the localization of specific DNA or RNA sequences within tissue sections and cytology samples using labeled complementary strands. The target gene can be visualized through brightfield or fluorescence microscopy. Compared to IHC, which broadly localizes proteins within tissues, ISH offers superior sensitivity. ISH not only identifies cells positive for a specific DNA or RNA sequence but also quantifies their level of positivity within individual cells. This makes ISH particularly valuable for studies requiring precise gene-level data within a morphological context.
We offer all methods of probe detection to uncover the morphological data of your samples. Our ISH services include fluorescence in situ hybridization (FISH), silver-enhanced in situ hybridization (SISH), and chromogenic in situ hybridization (CISH). For studies requiring a more comprehensive view, we also offer multiplex assays that combine ISH with immunohistochemistry (IHC) on the same slide, enabling simultaneous gene and protein expression analysis in situ.
CellCarta has assembled a chain of semi-automated equipment to optimize and standardize ISH processing. FISH assays are performed using the Abbott VP2000 with hybridization steps completed on calibrated ThermoBrite heating modules. SISH assays are run on the Benchmark XT and Ultra automated systems. Multiplex CISH with IHC is performed on the Leica Bond autostainer. FISH signal evaluation and quantification is conducted using Zeiss Axioplan microscopes paired with the BioView imaging system. Chromogenic ISH slides are captured using whole slide digital imaging. All equipment is extensively qualified and undergoes regular quality checks.
CellCarta’s ISH services can be implemented at any stage of therapeutic development, from exploratory studies through to late-phase clinical trials and companion diagnostic (CDx) development. Our platforms are designed to scale with your program: the semi-automated FISH process can handle up to 50 slides per run, while the automated SISH system accommodates up to 30 slides per run. We have successfully deployed cytogenetic FISH assays for the diagnosis, prognosis, and therapeutic surveillance of cancer patients in the clinical setting.
Yes. CellCarta has extensively evaluated RNAscope (ACD) nucleic acid in situ hybridization technology for mRNA detection in FFPE tissue. RNAscope is validated for use on FFPE cell preparations and can be requested for any target of interest. As each specimen type presents unique challenges, the technology will undergo custom validation to fine-tune the procedure to your specific samples. Client specimens are tested during an assay optimization phase, and results determine whether further validation steps are required.
